Lantheus Holdings (LNTH) recently drew attention after its investigational PET/CT agent LNTH-2513 (18F-GP1) received SNMMI’s Image of the Year award, backed by trial data on diagnosing acute lower-extremity deep vein thrombosis.

The recent SNMMI recognition and upcoming Goldman Sachs healthcare conference appearance come as the stock trades at US$104.67, with a 30-day share price return of 11.46% and a year to date share price return of 55.60%, alongside a 5-year total shareholder return of 316.02%. This combination suggests momentum has been building over both shorter and longer timeframes.

If you are interested in how medical imaging and radiopharmaceutical advances could play out across the market, it may be worth scanning the 39 healthcare AI stocks

With Lantheus posting steady revenue and net income figures alongside strong recent share price gains and an intrinsic value estimate suggesting a discount, the key question is whether there is still an opportunity here or if markets are already pricing in future growth.

Most Popular Narrative: 1% Overvalued

The most followed narrative currently places Lantheus Holdings' fair value at $104.08, almost level with the last close of $104.67, so expectations are finely balanced.

The expansion of Lantheus's Alzheimer's disease imaging franchise, including the recent FDA label expansion for Neuraceq and late-stage tau-targeted radiodiagnostic MK-6240, positions the company to capture accelerating demand driven by broader adoption of amyloid-targeted therapies and increased focus on early diagnosis. This is likely to drive strong revenue growth as the U.S. PET imaging market for Alzheimer's is expected to exceed $1.5 billion by 2030.

Interested in why this narrative gives Lantheus a higher fair value despite only moderate growth assumptions and a lower discount rate than before? The key lies in how future margins, earnings expectations and a richer future P/E multiple interact to justify that price target, even as analysts temper some of their profit forecasts.

Result: Fair Value of $104.08 (OVERVALUED)

However, this hinges on PYLARIFY holding up under pricing pressure and reimbursement shifts, as well as on acquisitions contributing more than low single digit EPS accretion over time.

Another Take on Value: What the P/E Says

The analyst narrative frames Lantheus as about 1% overvalued around $104 per share, yet the current P/E of 24.4x sits slightly below the fair ratio of 25.3x and well below the peer average of 37.6x. If growth cools and risks show up, that valuation gap may not appear as comfortable.

To see how those earnings multiples stack up in more detail, including how they compare across peers and where the fair ratio suggests the market could shift, check out the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment finely balanced between risks and rewards, it makes sense to move quickly, review the underlying data yourself, and form a clear stance around the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If Lantheus has sharpened your interest, do not stop here. Broader context across sectors can help you stress test your thesis and spot fresh angles.

• Zero in on potential mispricings by reviewing companies highlighted in the 47 high quality undervalued stocks before the crowd pays closer attention.
• Strengthen your downside protection by checking stocks in the 68 resilient stocks with low risk scores that pair resilience with measured risk profiles.
• Get ahead of the market by scanning the screener containing 20 high quality undiscovered gems where quieter opportunities may still be flying under most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.